Expression of Ku86 confers favorable outcome of tonsillar carcinoma treated with radiotherapy

Head and Neck

Volumn 25, Issue 4, 2003, Pages 313-321

  Friesland, Signe ^a   Kanter Lewensohn, Lena ^a   Tell, Roger ^a   Munck Wikland, Eva ^a   Lewensohn, Rolf ^a   Nilsson, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

DNA PK; MDM2; p53; Radiosensitivity; Tonsillar cancer

Indexed keywords

DNA DAMAGE RECOGNITION COMPLEX; DNA PK; PROTEIN; PROTEIN KU 86; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; TONSIL CARCINOMA; TUMOR BIOPSY;

AGED; AGED, 80 AND OVER; ANTIGENS, NUCLEAR; ARABIDOPSIS PROTEINS; CARCINOMA, SQUAMOUS CELL; DNA HELICASES; DNA-ACTIVATED PROTEIN KINASE; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SURVIVAL RATE; TONSILLAR NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037379412     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.10199     Document Type: Article

References (50)

1. Million RR, Cassisi JN. Management of head and neck cancer: a multidisciplinary approach, 2nd ed. Philadelphia: Lippincott Company; 1994. 104-114;401-429.
2. Perez CA, Purdy JA, Breaux SR, Ogura JH, von Essen S. Carcinoma of the tonsillar fossa: a nonrandomized comparison of preoperative radiation and surgery or irradiation alone: long-term results. Cancer 1982;50:2314-2322.
3. Chiesa F, Tradati N, Mauri S, et al. Prognostic factors in head and neck oncology: a critical appraisal for use in clinical practice. Anticancer Res 1998;18:4769-4776.
4. Hall SF, Groome PA, Rothwell D, Dixon PF. Using TNM staging to predict survival in patients with squamous cell carcinoma of head & neck. Head Neck 1999;21:30-38.
5. Janot F, Klijanienko J, Russo A, et al. Prognostic value of clinicopathological parameters in head and neck squamous cell carcinoma: a prospective analysis. Br J Cancer 1996;73:531-538.
6. Jaulerry C, Dubray B, Brunin F, et al. Prognostic value of tumor regression during radiotherapy for head and neck cancer: a prospective study [see comments]. Int J Radiat Oncol Biol Phys 1995;33:271-279.
7. Friesland S, Fernberg JO, Lundell G, Munck-Wikland E, Strander H, Lewensohn R. Prognostic impact of complete remission after preoperative irradiation of tonsillar carcinoma: a retrospective analysis of the radiumhemmet data, 1980-1995. Int J Radiat Oncol Biol Phys 1999;45:1259-1266.
8. Gottlieb TM, Jackson SP. The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen. Cell 1993;72:131-142.
9. Smith GC, Jackson SP. The DNA-dependent protein kinase. Genes Dev 1999;13:916-934.
10. Woo RA, McLure KG, Lees-Miller SP, Rancourt DE, Lee PW. DNA-dependent protein kinase acts upstream of p53 in response to DNA damage. Nature 1998;394:700-704.
11. Nussenzweig A, Chen C, da Costa Soares V, et al. Requirement for Ku80 in growth and immunoglobulin V(D)J recombination. Nature 1996;382:551-555.
12. Kuhn A, Gottlieb TM, Jackson SP, Grummt I. DNA-dependent protein kinase: a potent inhibitor of transcription by RNA polymerase I. Genes Dev 1995;9:193-203.
13. Giffin W, Torrance H, Rodda DJ, Prefontaine GG, Pope L, Hache RJ. Sequence-specific DNA binding by Ku autoantigen and its effects on transcription. Nature 1996;380:265-268.
14. Nussenzweig A, Sokol K, Burgman P, Li L, Li GC. Hypersensitivity of Ku80-deficient cell lines and mice to DNA damage: the effects of ionizing radiation on growth, survival, and development. Proc Natl Acad Sci USA 1997;94:13588-13593.
15. Gu Y, Seidl KJ, Rathbun GA, et al. Growth retardation and leaky SCID phenotype of Ku70-deficient mice. Immunity 1997;7:653-665.
16. Blunt T, Finnie N, Taccioli GE, et al. Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation. Cell 1995;80:813-823.
17. Smider V, Rathmell WK, Lieber MR, Chu G. Restoration of X-ray resistance and V(D)J recombination in mutant cells by Ku cDNA. Science 1994;266:288-291.
18. Taccioli GE, Gottlieb TM, Blunt T, et al. Ku80: product of the XRCC5 gene and its role in DNA repair and V(D)J recombination. Science 1994;265:1442-1445.
19. Kirchgessner CU, Patil CK, Evans JW, et al. DNA-dependent kinase (p350) as a candidate gene for the murine SCID defect. Science 1995;267:1178-1183.
20. Lees-Miller SP, Godbout R, Chan DW, et al. Absence of p350 subunit of DNA-activated protein kinase from a radiosensitive human cell line. Science 1995;267:1183-1185.
21. Sirzen F, Nilsson A, Zhivotovsky B, Lewensohn R. DNA-dependent protein kinase content and activity in lung carcinoma cell lines: correlation with intrinsic radiosensitivity. Eur J Cancer 1999;35:111-116.
22. Wilson CR, Davidson SE, Margison GP, Jackson SP, Hendry JH, West CM. Expression of Ku70 correlates with survival in carcinoma of the cervix [In Process Citation]. Br J Cancer 2000;83:1702-1706.
23. Kastan MB, Zhan Q, el-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992;71:587-597.
24. Lin D, Shields MT, Ullrich SJ, Appella E, Mercer WE. Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc Natl Acad Sci USA 1992;89:9210-9214.
25. Giaccia AJ, Kastan MB. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 1998;12:2973-2983.
26. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-6311.
27. Bristow RG, Benchimol S, Hill RP. The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiother Oncol 1996;40:197-223.
28. Freedman DA, Levine AJ. Regulation of the p53 protein by the MDM2 oncoprotein - thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res 1999;59:1-7.
29. Momand J, Wu HH, Dasgupta G. MDM2 - master regulator of the p53 tumor suppressor protein. Gene 2000;242:15-29.
30. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993;7:1126-1132.
31. Mendrysa SM, Perry ME. The p53 tumor suppressor protein does not regulate expression of its own inhibitor, MDM2, except under conditions of stress. Mol Cell Biol 2000;20:2023-2030.
32. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997;91:325-334.
33. AJCC Cancer staging manual, 5th ed. Philadelphia: J. B. Lippincott; 1997.
34. Shim DM, Lee JS, Lippman SM, et al. p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:519-529.
35. Kasten U, Borgmann K, Burgmann P, Li G, Dikomey E. Overexpression of human Ku70/Ku80 in rat cells resulting in reduced DSB repair capacity with appropriate increase in cell radiosensitivity but with no effect on cell recovery. Radiat Res 1999;151:532-539.
36. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
37. Siles E, Villalobos M, Valenzuela MT, et al. Relationship between p53 status and radiosensitivity in human tumour cell lines. Br J Cancer 1996;73:581-588.
38. McIlwrath AJ, Vasey PA, Ross GM, Browns R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res 1994;54:3718-3722.
39. Kawashima K, Mihara K, Usuki H, Shimizu N, Namba M. Transfected mutant p53 gene increases X-ray-induced cell killing and mutation in human fibroblasts immortalized with 4-nitroquinoline 1-oxide but does not induce neoplastic transformation of the cells. Int J Cancer 1995;61:76-79.
40. Biard DS, Martin M, Rhun YL, et al. Concomitant p53 gene mutation and increased radiosensitivity in rat lung embryo epithelial cells during neoplastic development. Cancer Res 1994;54:3361-3364.
41. Langendijk JA, Thunnissen FB, Lamers RJ, et al. The prognostic significance of accumulation of p53 protein in stage III non-small cell lung cancer treated by radiotherapy. Radiother Oncol 1995;36:218-224.
42. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995;1:1029-1034.
43. Awwad S, Jaros E, Somes J, Lunec J. P53 overexpression in head and neck carcinoma and radiotherapy results [see comments]. Int J Radiat Oncol Biol Phys 1996;34:323-332.
44. Nacht M, Strasser A, Chan YR, et al. Mutations in the p53 and SCID genes cooperate in tumorigenesis. Genes Dev 1996;10:2055-2066.
45. Mayo LD, Turchi JJ, Berberich SJ. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res 1997;57:5013-5016.
46. Ganly I, Soutar DS, Brown R, Kaye SB. p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy. Br J Cancer 2000;82:392-398.
47. Jiang M, Shao ZM, Wu J, et al. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int J Cancer 1997;74:529-534.
48. Xiao ZX, Chen J, Levine AJ, et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995;375:694-698.
49. Martin K, Trouche D, Hagemeier C, Sorensen TS, La Thangue NB, Kouzarides T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 1995;375:691-694.
50. Moller MB, Nielsen O, Pedersen NT. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities. Mod Pathol 1999;12:1010-1016.